|1.||Feeley, B T: 1 article (03/2000)|
|2.||Park, A K: 1 article (03/2000)|
|3.||Poston, R S: 1 article (03/2000)|
|4.||Ennen, M P: 1 article (03/2000)|
|5.||Hoyt, E G: 1 article (03/2000)|
|6.||Robbins, R C: 1 article (03/2000)|
|7.||Vriens, P W: 1 article (03/2000)|
07/01/1999 - "The goal of this study is to determine the effects of ex vivo hyperbaric pressure administration of AS-ICAM-1 ODN and systemic anti-LFA-1 mAb treatment on reperfusion injury in the rat cardiac allograft model. "
07/01/1999 - "Pressure delivery of AS-ICAM-1 ODN with LFA-1 mAb reduces reperfusion injury in cardiac allografts."
07/01/1999 - "Ex vivo pressure mediated delivery of AS-ICAM-1 ODN decreases ICAM-1 protein expression, reduces reperfusion injury in rodent cardiac allografts, and is more effective than anti-LFA-1 mAb treatment alone."
07/01/1999 - "Combination of pressure administration of AS-ICAM-1 ODN and anti-LFA-1 mAb decreased wet weight ratios (77.1+/-0.93%, p < 0.05 vs saline), myeloperoxidase activity (2.88+/-0.44, p < 0.01 vs saline), and contraction band necrosis (6.75+/-5.67%, p < 0.05 vs saline). "
07/01/1999 - "Ex vivo administration of AS-ICAM-1 ODN led to decreases in percentage wet weight (77.1+/-0.83% vs 78.7+/-1.0%, p < 0.05), myeloperoxidase activity (3.14+/-0.72 vs 4.07+/-0.59, p < 0.05), contraction band necrosis (6.4+/-6.47% vs 21.1+/-7.43%, p < 0.01), and ICAM-1 protein expression determined by immunohistochemistry compared to saline controls. "
|1.||anti-LFA-1 monoclonal antibody (Odulimomab)
|2.||Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)
|3.||Lymphocyte Function-Associated Antigen-1 (LFA-1)
|1.||Homologous Transplantation (Allograft)